Topics:

Oncology and Hematology News and Journal Articles

FDA Approves Ramucirumab for Second-Line Treatment of mCRC

The FDA has approved ramucirumab, a human VEGFR2 antagonist in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer.

Recent Content

Colorectal tumors that lacked the ability to repair DNA were found to be highly responsive to checkpoint blockade with the anti–PD-1 drug pembrolizumab.

Ahead of the 2015 ASCO Annual Meeting, we are discussing the role of immunotherapy in genitourinary cancers with Susan F. Slovin, MD, PhD.

Jennifer Ligibel, MD, discusses the link between obesity and cancer as part of ASCO's obesity initiative ahead of this year's ASCO Annual Meeting.

Aflatoxin, a naturally occurring toxin produced by certain types of molds, has been found to be associated with an increased risk of gallbladder cancer.

We discuss some of the anticipated multiple myeloma trials with Sagar Lonial, MD, ahead of the 2015 American Society of Clinical Oncology Annual Meeting.

A survey showed that cancer patients' attitudes about alternative medicines explained their use more so than demographics and clinical characteristics.

A large majority of prostate tumors sequenced as part of a comprehensive precision medicine study have mutations that can be targeted with available therapies.

By clicking Accept, you agree to become a member of the UBM Medica Community.